IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension
Zhu, Jun-Ren1; Sun, Ning-Ling2; Yang, Kan3; Hu, Jian4; Xu, Geng5; Hong, Huashan6; Wang, Ruonan7; Tu, Ying-Mei7; Ritter, Shannon8; Keefe, Deborah8; Trial Investigators1
关键词Aliskiren Asian Cough Ramipril
刊名HYPERTENSION RESEARCH
2012
DOI10.1038/hr.2011.150
35期:1页:28-33
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Peripheral Vascular Disease
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]ANGIOTENSIN-CONVERTING-ENZYME ; PLACEBO-LIKE TOLERABILITY ; DOSE-DEPENDENT EFFICACY ; ANTIHYPERTENSIVE EFFICACY ; JAPANESE PATIENTS ; PREVALENCE ; COUGH ; CHINESE ; GUIDELINES ; TRIAL
英文摘要

This 8-week, randomized, double-blind, parallel-group study compared the efficacy and safety of aliskiren with ramipril in Asian patients with mild to moderate hypertension. Following a 2- to 3-week placebo run-in period, patients with mean sitting diastolic blood pressure (msDBP) >= 95 and <110 mm Hg were randomized to receive once daily dose of either aliskiren 75, 150, 300mg or ramipril 5mg for 8 weeks. Efficacy variables were the changes in msDBP and mean sitting systolic BP (msSBP) and BP control rates (<140/90 mm Hg). Safety was assessed by recording adverse events (AEs) and serious AEs (SAEs). Of 1316 randomized patients, 1160 (88.1%) completed the study. At the study endpoint, patients on aliskiren had greater mean BP reductions (14.39/11.63 mm Hg for 300 mg; 12.16/10.04 mm Hg for 150 mg; 12.24/10.66 mm Hg for 75 mg) than those on 5mg ramipril (11.46/9.19 mm Hg). All aliskiren doses were statistically non-inferior (P<0.0001) to ramipril in reducing msDBP. The reduction in BP for aliskiren 300 mg was statistically superior vs. ramipril (P<0.002). Blood pressure control rates were higher for aliskiren (300 mg, 52.29%; 150 mg, 48.11%; 75 mg, 45.68%) than for ramipril (5 mg, 43.7%); the difference for aliskiren 300 mg vs. ramipril 5mg was statistically significant (P<0.05). Aliskiren was well tolerated with a fourfold lower incidence of cough (0.6-1.2%) compared with ramipril (5.2%). SAEs were rare in this study (0.5%). Aliskiren produced greater BP reductions with a lower incidence of cough than ramipril in Asian patients with mild to moderate hypertension. Hypertension Research (2012) 35, 28-33; doi:10.1038/hr.2011.150; published online 8 September 2011

语种英语
WOS记录号WOS:000299168900007
资助机构Novartis Pharma AG, Basel, Switzerland
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51276
专题北京大学第二临床医学院_心血管内科
作者单位1.Novartis Pharmaceut, E Hanover, NJ USA
2.Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai 200032, Peoples R China
3.Peking Univ, Peoples Hosp, Dept Cardiol, Beijing 100871, Peoples R China
4.Cent S Univ, Xiangya Hosp 3, Dept Cardiol, Changsha, Hunan, Peoples R China
5.China Med Univ, Affiliated Hosp 1, Dept Cardiol, Shenyang, Peoples R China
6.Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Cardiol, Hangzhou 310003, Zhejiang, Peoples R China
7.Fujian Med Univ, Union Hosp, Dept Cardiol, Fuzhou, Peoples R China
8.Beijing Novartis Pharma Co Ltd, Dept Cardiol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Zhu, Jun-Ren,Sun, Ning-Ling,Yang, Kan,et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension[J]. HYPERTENSION RESEARCH,2012,35(1):28-33.
APA Zhu, Jun-Ren.,Sun, Ning-Ling.,Yang, Kan.,Hu, Jian.,Xu, Geng.,...&Trial Investigators.(2012).Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.HYPERTENSION RESEARCH,35(1),28-33.
MLA Zhu, Jun-Ren,et al."Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension".HYPERTENSION RESEARCH 35.1(2012):28-33.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhu, Jun-Ren]的文章
[Sun, Ning-Ling]的文章
[Yang, Kan]的文章
百度学术
百度学术中相似的文章
[Zhu, Jun-Ren]的文章
[Sun, Ning-Ling]的文章
[Yang, Kan]的文章
必应学术
必应学术中相似的文章
[Zhu, Jun-Ren]的文章
[Sun, Ning-Ling]的文章
[Yang, Kan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。